Danielle Brill
Stock Analyst at Truist Securities
(3.95)
# 624
Out of 5,105 analysts
92
Total ratings
48.75%
Success rate
12.66%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $80 → $105 | $98.58 | +6.51% | 3 | Nov 10, 2025 | |
| IRON Disc Medicine | Maintains: Buy | $86 → $114 | $91.85 | +24.12% | 7 | Nov 10, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $165 → $172 | $152.80 | +12.57% | 7 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Buy | $66 → $80 | $75.15 | +6.45% | 2 | Oct 30, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $459 → $535 | $397.55 | +34.57% | 2 | Oct 17, 2025 | |
| IMVT Immunovant | Initiates: Hold | $16 | $26.42 | -39.44% | 5 | Oct 14, 2025 | |
| UPB Upstream Bio | Initiates: Buy | $47 | $27.14 | +73.18% | 1 | Oct 14, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $56 | $42.13 | +32.92% | 1 | Oct 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $452.04 | - | 3 | Sep 3, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $40.51 | +18.49% | 8 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $64 | $19.76 | +223.89% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $26.51 | +13.16% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $21.87 | +9.76% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $19.51 | +166.53% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $17.98 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $53.31 | +48.19% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $13.87 | +29.78% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $21.53 | +596.70% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $174.10 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $877.94 | -31.09% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $27.15 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $44.06 | +13.48% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $27.27 | +87.02% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $9.80 | +920.93% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $75.64 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.38 | - | 5 | Jun 27, 2023 |
Palvella Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $80 → $105
Current: $98.58
Upside: +6.51%
Disc Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $91.85
Upside: +24.12%
Neurocrine Biosciences
Oct 30, 2025
Reiterates: Buy
Price Target: $165 → $172
Current: $152.80
Upside: +12.57%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Buy
Price Target: $66 → $80
Current: $75.15
Upside: +6.45%
Alnylam Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $459 → $535
Current: $397.55
Upside: +34.57%
Immunovant
Oct 14, 2025
Initiates: Hold
Price Target: $16
Current: $26.42
Upside: -39.44%
Upstream Bio
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $27.14
Upside: +73.18%
Dianthus Therapeutics
Oct 14, 2025
Initiates: Buy
Price Target: $56
Current: $42.13
Upside: +32.92%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $452.04
Upside: -
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $40.51
Upside: +18.49%
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $19.76
Upside: +223.89%
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $26.51
Upside: +13.16%
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $21.87
Upside: +9.76%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $19.51
Upside: +166.53%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $17.98
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $53.31
Upside: +48.19%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $13.87
Upside: +29.78%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $21.53
Upside: +596.70%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $174.10
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $877.94
Upside: -31.09%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $27.15
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $44.06
Upside: +13.48%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $27.27
Upside: +87.02%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $9.80
Upside: +920.93%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $75.64
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.38
Upside: -